352 related articles for article (PubMed ID: 10908539)
21. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
Deane KH; Spieker S; Clarke CE
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004554. PubMed ID: 15495119
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527
[TBL] [Abstract][Full Text] [Related]
23. Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease.
Ramaker C; Hilten JJ
Cochrane Database Syst Rev; 2002; (2):CD003634. PubMed ID: 12076493
[TBL] [Abstract][Full Text] [Related]
24. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease.
Wong KS; Lu CS; Shan DE; Yang CC; Tsoi TH; Mok V
J Neurol Sci; 2003 Dec; 216(1):81-7. PubMed ID: 14607306
[TBL] [Abstract][Full Text] [Related]
25. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease.
Pinter MM; Rutgers AW; Hebenstreit E
J Neural Transm (Vienna); 2000; 107(11):1307-23. PubMed ID: 11145006
[TBL] [Abstract][Full Text] [Related]
26. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
27. Bromocriptine versus levodopa in early Parkinson's disease.
van Hilten JJ; Ramaker CC; Stowe R; Ives NJ
Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD002258. PubMed ID: 17943771
[TBL] [Abstract][Full Text] [Related]
28. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
Marsden CD
Drugs; 1998; 55 Suppl 1():17-22. PubMed ID: 9483166
[TBL] [Abstract][Full Text] [Related]
29. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
Etminan M; Samii A; Takkouche B; Rochon PA
Drug Saf; 2001; 24(11):863-8. PubMed ID: 11665873
[TBL] [Abstract][Full Text] [Related]
30. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group.
Clin Neuropharmacol; 2000; 23(1):34-44. PubMed ID: 10682229
[TBL] [Abstract][Full Text] [Related]
31. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
[TBL] [Abstract][Full Text] [Related]
33. Bromocriptine for levodopa-induced motor complications in Parkinson's disease.
van Hilten JJ; Ramaker C; Van de Beek WJ; Finken MJ
Cochrane Database Syst Rev; 2000; 1998(2):CD001203. PubMed ID: 10796755
[TBL] [Abstract][Full Text] [Related]
34. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
[TBL] [Abstract][Full Text] [Related]
35. Dopamine agonists versus levodopa monotherapy in early Parkinson's disease for the potential risks of motor complications: A network meta-analysis.
Zhang Q; Chen X; Chen F; Wen S; Zhou C
Eur J Pharmacol; 2023 Sep; 954():175884. PubMed ID: 37385577
[TBL] [Abstract][Full Text] [Related]
36. Ropinirole: a review of its use in the management of Parkinson's disease.
Matheson AJ; Spencer CM
Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
[TBL] [Abstract][Full Text] [Related]
37. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.
Radad K; Gille G; Rausch WD
Pharmacol Rep; 2005; 57(6):701-12. PubMed ID: 16382188
[TBL] [Abstract][Full Text] [Related]
38. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Inzelberg R; Schechtman E; Nisipeanu P
Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
[TBL] [Abstract][Full Text] [Related]
39. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
Parkinson Study Group
JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889
[TBL] [Abstract][Full Text] [Related]
40. Amantadine in Parkinson's disease.
Crosby N; Deane KH; Clarke CE
Cochrane Database Syst Rev; 2003; 2003(1):CD003468. PubMed ID: 12535476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
